Page last updated: 2024-11-10

thymic factor, circulating

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

thymalin: see also thymarin [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Thymic Factor, Circulating: A thymus-dependent nonapeptide found in normal blood. Stimulates the formation of E rosettes and is believed to be involved in T-cell differentiation. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3085284
CHEMBL ID2106455
SCHEMBL ID2109423
MeSH IDM0021445
PubMed CID71300623
MeSH IDM0021445

Synonyms (35)

Synonym
MLS000028679
smr000058784
nonathymulin
thymulin
thymuline
(2s)-4-amino-2-[[(2s)-2-[[2-[[2-[[(2s)-5-amino-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-5-oxopyrrolidine-2-carbonyl]amino]propanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino
thymalin
9h198d04wl ,
nonathymulin [inn]
n(sup 2)-(n-(n-(n-(n(sup 2)-(n-(n(sup 2)-(n-(-5-oxo-l-prolyl)-l-alanyl)-l-lysyl)-l-seryl)-l-glutaminyl)glycyl)glycyl)-l-seryl)-l-asparagine
thymulin (pig peptide moiety)
unii-9h198d04wl
(sup 2)n-(n-(n-(n-(sup 2)n-(n-(sup 2)n-(n-(-5-oxo-l-prolyl)-l-alanyl)-l-seryl)-l-glutaminyl)glycyl)glycyl)-l-seryl)-l-asparagine.
CHEMBL2106455
thymic factor
l-asparagine, 5-oxo-l-prolyl-l-alanyl-l-lysyl-l-seryl-l-glutaminylglycylglycyl-l-seryl-
SCHEMBL2109423
DTXSID10213801 ,
thymulin, lyophilized powder
(3s,6s,9s,12s,21s,24s)-24-(2-amino-2-oxoethyl)-12-(3-amino-3-oxopropyl)-6-(4-aminobutyl)-9,21-bis(hydroxymethyl)-3-methyl-1,4,7,10,13,16,19,22-octaoxo-1-((s)-5-oxopyrrolidin-2-yl)-2,5,8,11,14,17,20,23-octaazapentacosan-25-oic acid
mfcd00076882
pyroglu-ala-lys-ser-gln-gly-gly-ser-asnoh
pglu-ala-lys-ser-gln-gly-gly-ser-asn-oh
Q2007601
GLXC-25916
nonathymulinum
nonathymuline
dtxcid00136292
nonatimulina
thymic factor, circulating
facteur thymique serique
78922-62-0
oligopeptide thymic factor
DTXSID40229374
(2s)-4-amino-2-[[(2s)-2-[[2-[[2-[[(2s)-5-amino-2-[[2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-5-oxopyrrolidine-2-carbonyl]amino]propanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-o

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Whether the recovery of thymulin production in GH deficient children by GH therapy is mediated by IGF-1 or by bioavailability of zinc ions remains to be established."( Thymic endocrine activity in children with idiopathic growth-hormone deficiency.
De Min, C; Fabris, N; Mocchegiani, E; Paolucci, P; Sartorio, A; Travaglini, P, 1991
)
0.28
" These data suggest that the thymic defect, followed by impaired peripheral immune efficiency, may largely depend by the low peripheral zinc bioavailability to saturate all thymulin molecules produced."( Zinc, thymic endocrine activity and mitogen responsiveness (PHA) in piglets exposed to maternal aflatoxicosis B1 and G1.
Bonomi, A; Borghetti, P; Cabassi, E; Corradi, A; DeAngelis, E; Fabris, N; Mocchegiani, E; Santarelli, L; Tibaldi, A, 1998
)
0.3
" The in vitro addition of zinc to plasma samples induces a recovery of the thymulin active form, suggesting low zinc bioavailability as the cause of impaired thymic functions with consequent CD4(+) depletion."( Therapeutic application of zinc in human immunodeficiency virus against opportunistic infections.
Mocchegiani, E; Muzzioli, M, 2000
)
0.31
" Therefore, high MTs may become to protective in young age to harmful during ageing leading to low zinc ion bioavailability for many body homeostatic mechanisms, including brain function."( Interrelationships among brain, endocrine and immune response in ageing and successful ageing: role of metallothionein III isoform.
Cipriano, C; Gasparini, N; Giacconi, R; Mocchegiani, E; Muzzioli, M; Orlando, F, 2003
)
0.32
" The absolute bioavailability approached 100%, indicating a complete release from the depot, in spite of rilpivirine concentrations still being high at the injection site(s) 3 months after administration in dogs."( Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation.
Baert, L; Borghys, H; Bouche, MP; Hoeben, E; Looszova, A; van 't Klooster, G; van Velsen, F, 2010
)
0.36

Dosage Studied

ExcerptRelevanceReference
" Drug dosage was 1 mg."( [Effect of thymalin and epithalamin on the metastasis of experimental tumors irradiated with pulsed laser radiation].
Moskalik, KG, 1987
)
0.27
"Two randomised double blind, placebo controlled trials have been carried out to assess the effectiveness of nonathymulin, a synthetic thymic peptide hormone, in the treatment of rheumatoid arthritis (RA) and to compare three different dosage schedules (1, 5, and 10 mg/day)."( Nonathymulin in rheumatoid arthritis: two double blind, placebo controlled trials.
Amor, B; Bach, JF; Dardenne, M; Dougados, M; Mery, C, 1987
)
0.27
" Perifusion of young and senescent AP cells with thymulin doses, ranging from 10(-8) to 10(-5) M, gave a logarithmic dose-response pattern of GH."( Growth hormone-releasing activity of thymulin on pituitary somatotropes is age dependent.
Brown, OA; Dardenne, M; Goya, RG; Pléau, J; Sosa, YE, 1999
)
0.3
" Dose-response experiments found that the 50 ng/100 g body weight (Bwt) dose significantly depressed the cytolytic activity of the NK cells in comparison to either the 10 ng/100 g Bwt dose or the control."( In vivo thymulin treatments enhance avian lung natural killer cell cytotoxicity in response to infectious bronchitis virus.
Marsh, JA; Oliver, MA, 2003
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (734)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990394 (53.68)18.7374
1990's185 (25.20)18.2507
2000's102 (13.90)29.6817
2010's45 (6.13)24.3611
2020's8 (1.09)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 8.78

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index8.78 (24.57)
Research Supply Index5.51 (2.92)
Research Growth Index4.29 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (8.78)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials12 (5.13%)5.53%
Trials10 (1.65%)5.53%
Reviews6 (2.56%)6.00%
Reviews52 (8.58%)6.00%
Case Studies4 (1.71%)4.05%
Case Studies11 (1.82%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other212 (90.60%)84.16%
Other533 (87.95%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]